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Background: Little is known about the release of apopto-
tic proteins during periodontal breakdown. This pilot study
investigates the presence of factors associated with apopto-
sis in serum, saliva, and gingival crevicular fluid (GCF) and
their association with periodontal disease severity and ac-
tivity.
Methods: GCF, whole saliva, and serum were obtained
from 47 adult patients with chronic periodontitis (CP) and
10 healthy controls. Clinical measurements, including prob-
ing depth (PD), clinical attachment level (CAL), and radio-
graphs, were used to classify patients into healthy, mild,
and moderate/severe CP groups. Enzyme-linked immuno-
sorbent assays were used to measure apoptosis or DNA frag-
mentation in GCF and active caspase-3, soluble Fas (sFas),
and sFas ligand (sFasL) in saliva and serum. Western immu-
noblotting was used to detect Fas, FasL, sFasL, and caspase-3
expression in GCF.
Results: DNA fragmentation was positively correlated with
PD and CAL regardless of patient disease status (P <0.001).
sFas and sFasL were present in saliva and serum, but there
were no differences between groups. In GCF, the greater
odds of detecting Fas, sFasL, and caspase-3 increased
with increasing PD and CAL (P <0.05). In addition, sites
with inflammation and PD ‡5 mm had significantly greater
odds of exhibiting Fas, sFasL, and caspase-3 expression
compared with sites without inflammation and PD <5 mm
(P <0.05). Caspase-3 was not detected in saliva or serum.
At the patient level, only FasL and disease status were signif-
icantly correlated (P <0.05).
Conclusion: Factors associated with apoptosis were
detected in GCF in patients with CP. J Periodontol 2014;85:
1086-1095.
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T
he mechanisms responsible for
periodontal disease progression
remain unclear. However, recent
studies suggested that apoptosis may
be one mechanism underlying the path-
ophysiology involved with the pro-
gression of periodontitis.1,2 Also known
as ‘‘programmed cell death,’’3 apoptosis
plays a critical role in the regulation of
the host immune response and in-
flammation and can be modulated by
various stimuli, including cytokines,
bacterial and viral infections, immune
cells themselves, and changes in growth
factors, nutrients, and the extracellular
matrix.4
One of the best-defined apoptotic
pathways is mediated by the death re-
ceptor Fas and Fas ligand (FasL) com-
plex. The Fas receptor is expressed on
many cell types that include gingival
fibroblasts, skin keratinocytes, and T
cells5-7 Apoptotic cells are present in
diseased gingiva.8 During cell apoptosis,
a sequential activation of cysteine pro-
teases, called caspases, plays a central
role in the execution phase of apoptosis.
Caspase-3 is one of the key executor
caspases that regulates a number of
critical cellular substrates and when
active has been easily detected in cells
undergoing apoptosis.9 Eventually, the
caspase cascade culminates in the
cleavage of DNA into fragments, a hall-
mark of apoptosis.
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A number of apoptotic markers have been shown
to increase in the presence of disease. Fas and FasL
were found at higher levels in autoimmune dis-
eases,10,11 atherosclerosis, coronary disease,12,13
cancer,14-16 rheumatoid arthritis,17 and hepatitis.18
Caspase-3, another hallmark of apoptosis, has also
been detected in inflammatory diseases, including
rheumatoid arthritis.18,19 In the periodontium, ex-
pression of apoptosis-associated genes were shown
to increase when healthy gingival tissue was exposed
to pathogenic periodontal bacteria.20 Furthermore,
Fas and FasL were associated with chronic peri-
odontitis (CP).21
There is a critical need for the development of
more advanced diagnostic methods to predict the
presence of more severely inflamed periodontal sites
and to potentially determine the risk of an inactive
site becoming active. Analysis of apoptotic markers
in gingival crevicular fluid (GCF), saliva, and serum
show potential for this application; however, studies
in this area are lacking. The aim of this study is
to determine whether DNA fragmentation and
apoptosis-associated proteins from GCF, saliva,
and serum were associated with periodontal disease
status and whether these molecules could be used as
markers to determine more severely inflamed sites,
which could be a predictor of periodontal disease
activity.
MATERIALS AND METHODS
A single-center cross-sectional study of patients
with or without periodontal disease was conducted
at the Michigan Center for Oral Health Research at
the University of Michigan from 2006 to 2009 after
University of Michigan Institutional Review Board
approval was obtained. Fifty-seven adult patients
(26 males and 31 females, aged 28 to 79 years;
mean age: 52.45 years) were recruited from the
surrounding community after giving written consent
(Table 1). Participants were excluded from the
study if they: 1) had <20 teeth; 2) were pregnant
or suffered from metabolic bone diseases, auto-
immune disease, uncontrolled diabetes, or post-
menopausal osteoporosis; 3) had a history of
periodontal therapy; or 4) received antibiotics or
long-term non-steroidal anti-inflammatory drugs
within the past 3 months. Participants were en-
rolled in three groups according to criteria de-
scribed by Ramseier et al.:22 1) a healthy/gingivitis
group with £3-mm clinical attachment level (CAL),
no probing depth (PD) ‡4 mm, and no radio-
graphic alveolar bone loss; 2) a mild CP group with
at least four sites with radiographic bone loss, PD
‡4 mm, and <30% of sites with CAL >3 mm; and
3) a moderate/severe CP group with at least four
sites with radiographic bone loss, PD ‡4 mm, and
>30% of sites with CAL >3 mm.
Table 1.
Patient Demographics and Clinical Characteristics
Characteristic Overall Healthy Group Mild CP Group Moderate/Severe CP Group P values
Participants (n) 57 8 31 18
Males (n [%]) 26 (45.6) 1 (12.5) 11 (35.5) 14 (77.78%) Pr = 0.002
Females (n [%]) 31 (54.4) 7 (87.5) 20 (64.52) 4 (22.2%)
Smokers (n [%]) 21 (36.84) 1 (12.5) 9 (29) 11 (61.11%) Pr = 0.03
White (n [%]) 40 (70.18) 6 (75) 22 (71) 12 (66.7%) Pr = 0.90
Mean no. of teeth 25 27 25 24
Mean age (years) 52.45 47.12 53.77 52.55 0.28
Sites with BOP (%) 54 20 58 66 <0.001
Sites with gingival redness (%) 73 43 75 84 <0.001
Sites with plaque (%) 68 33 74 82 <0.001
Sites sampled (n) 1,336 210 717 409
Mean – SD PD (mm) 2.58 1.8 – 0.56 2.66 – 1.14 3.55 – 1.6 <0.001
Sites with PD ‡4 mm 16 0 12.6 (8%) 31.8 (21%) <0.001
Mean – SD CAL (mm) 2.12 0.8 – 0.86 2.19 – 1.45 3.6 – 1.98 <0.001
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Clinical Measurements
Interexaminer calibration was performed among
examiners (HA, ML, and CK) on a periodic basis, and
a k score of 0.8 or more was maintained throughout
the study. All teeth except third molars were as-
sessed for periodontal clinical measures. Clinical
parameters, including PD, CAL, and bleeding on
probing (BOP), were measured at six sites per tooth.
Other clinical measures included dichotomous
measures of plaque accumulation index (PI) and
gingival redness index (GI) as described previously
by Haffajee et al.23
Whole Saliva Collection
Unstimulated or resting whole saliva was collected
from all participants at the beginning of the ap-
pointment by passive drooling into a graduated sterile
tube. The collection was completed as soon as 2 mL
whole saliva was collected or 15 minutes of sampling
time elapsed. The samples were placed on ice, mixed
with 20 mL protease inhibitor cocktail,‡ vortexed and
aliquoted in equal quantities into six centrifuge tubes,
and stored at -80C until additional analysis.
Serum Collection
Six milliliters of blood were drawn by a registered
nurse via venipuncture and collected in serum sep-
arator tubes. The specimens were allowed to clot
for 30 minutes and centrifuged for 4.5 minutes at
4,450 rpm, and then the serum was aliquoted into
six cryovials and stored at -80C until additional
analysis.
GCF Collection and Sampling
GCF from the mesio-buccal site of each tooth was
collected using paper strips.§ To minimize contam-
ination, all clinically detectable supragingival plaque
was removed, and the area was isolated with cotton
rolls and gently air dried before sampling. During
sampling, the paper strip was inserted below the
gingival margin until slight resistance was felt, held in
place for 30 seconds, and then removed. GCF vol-
ume was measured using a calibrated machine.i
Strips that were contaminated with saliva, blood, or
plaque were discarded. After volume determination,
strips were stored in sterile collection tubes that were
labeled with tooth numbers and contained a pre-
aliquoted protease inhibitor cocktail and then stored
at -80C. Before analysis, the absorbed fluid was
eluted from each strip into 135 mL lysis buffer (100
mL 1 mM phenylmethylsulfonyl fluoride in 1 mL ra-
dioimmunoprecipitation assay buffer)¶ for a total
elution volume of 1.235 mL.
Sample Analyses
Enzyme-linked immunosorbent assays. Whole sa-
liva and serum were used to quantify soluble Fas
(sFas), FasL, and active caspase by quantitative
sandwich enzyme-linked immunosorbent assay
(ELISA).# Briefly, whole saliva and serum samples
were thawed, 100 mL supernatant was added in
triplicate to ELISA plates, and the amounts of sFas,
FasL, and active caspase-3 were measured at 540-
and 570-nm wavelengths using a spectrophotome-
ter. For DNA fragmentation detection, the eluted GCF
samples were assayed for histone-associated DNA
fragments using a detection kit.**
Western immunoblotting. Western immunoblot-
ting was used to detect the expression of specific
apoptotic proteins in the GCF samples. Briefly, the
50-mL eluted GCF sample was mixed with 50 mL
sample buffer (950 mL Laemmli sample buffer plus
50 mL 2-mercaptoethanol),†† boiled for 5 minutes,
and divided into three aliquots of equal volume. The
molecular weight markers, controls (human oral
squamous cell carcinoma cells treated with cis-
platin), and equal volumes of samples (one tooth per
well) were loaded onto 10% to 12% sodium dodecyl
sulfate polyacrylamide gels and electrophoretically
resolved under standard conditions. Next, the pro-
teins were transferred onto polyvinylidene difluoride
membranes‡‡ using standard protocols. After
transfer, the membranes were incubated for 45
minutes in Tris-buffered saline (TBS) starting block§§
to block non-specific protein binding sites. Mem-
branes were washed three times for 10 minutes with
TBS and polysorbate 20 (TBST), separately in-
cubated with 1:400 dilution of mouse antihuman Fas,
mouse antihuman FasL, and mouse antihuman
caspase-3 overnight at 4C, and then washed in
TBST three times for 10 minutes each.ii Blots were
incubated with horseradish peroxidase-labeled anti-
mouse immunoglobulin G for 2 hours at room
temperature, and chemiluminescent peroxidase
substrate¶¶ was applied according to the instructions
of the manufacturer. Membranes were briefly ex-
posed to radiographic film, and densities of bands
were scanned and analyzed using a scanning den-
sitometer and imaging software.##
Variations in the volume and protein sample
loaded were corrected by assessing the targeted
apoptotic proteins using a binary scale. The presence
of each protein band was scored by one independent
‡ P2714, Sigma-Aldrich, St. Louis, MO.
§ Oraflow, Smithtown, NY.
i Oraflow.
¶ Sigma-Aldrich.
# R&D Systems, Minneapolis, MN.
** Cell Death Detection ELISA kit PLUS, Roche Diagnostics, Indianapolis,
IN.
†† Bio-Rad, Hercules, CA.
‡‡ Millipore, Billerica, MA.
§§ Starting block T2 (TBS) blocking buffer 37543, Thermo Fisher
Scientific, Waltham, MA.
ii Santa Cruz Biotechnology, Santa Cruz, CA.
¶¶ ECL-Plus detection system, Pierce, Thermo Scientific, Rockford, IL.
## ImageJ software, NIH, Bethesda, MD.
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observer (DD) and classified as negative or positive
based on comparison with positive controls in ac-
cordance with the technique used by Bersano et al.24
The presence of each of Fas, FasL, and active
caspase-3 protein was counted if a band at a specific
nuclear weight per antibody was detected at the
molecular weight for each protein and was consistent
with the positive control.
Data Analyses
The sample size calculation of 50 participants was
based on a previous study comparing GCF among
clinically healthy, mild/moderate CP, and severe CP
sites within patients.25 Data analysis was performed
using a statistical package.*** The unit of analysis
was tooth site, but the fact that sites were grouped
within a patient was also accounted for. The level of
significance was set at P £0.05. All data were ex-
pressed as mean – SE for each factor.
Differences between groups were analyzed using
x2 correlation for binary demographic variables (sex,
smoking status, and ethnicity), analysis of variance
(ANOVA) for age, Kruskal-Wallis test to compare the
mean proportions for BOP, GI, PD, and CAL, and
regression analysis to account for confounding var-
iables. GCF DNA fragmentation data were analyzed
using mixed models for continuous outcomes.
ANOVA was used to analyze data quantifying each of
Fas, FasL, and caspase-3 proteins from both saliva
and serum samples. Generalized estimating equa-
tions were used to assess the
relationship between the pres-
ence or absence of the apo-
ptosis markers and PD, CAL,
BOP, GI, and disease status.
Because the outcome variable
was binary, results were pre-
sented in terms of odds of
presence (odds ratio [OR] of
presence of apoptosis factor
compared with its absence).
Data analysis was also per-
formed using two participant
groups based on the presence
of traditional accepted signs of
clinical disease activity (BOP,
GI, and PD ‡5 mm).26-29 CAL
was excluded because it could
represent past disease. Data
were analyzed by included sites
exhibiting both BOP and GI
(Classification 1), as well BOP
and GI and PD ‡5 mm (Clas-
sification 2).
RESULTS
Demographic Distribution of Patients and
Clinical Parameters
Fifty-seven patients were enrolled in the study: eight
in the healthy/gingivitis group, 31 in the mild CP
group, and 18 in the moderate/severe CP group. No
statistical differences among groups were found for
demographic variables except smoking status (P =
0.03) and sex (P = 0.002; Table 1). Regression
analysis was performed to account for the possible
confounding effects, although this did not appear to
influence the results. PD, AL, PI, BOP, and GI in the
healthy group were significantly less than in the
periodontitis groups (P <0.001).
Saliva Analyses
Both sFasL and sFas were detected in all saliva
samples, although caspase-3 was not. sFasL con-
centrations in saliva ranged from 3.01 to 33.7 pg/mL,
with a mean value of 11.32 – 5.49 pg/mL. sFas
concentrations in saliva ranged from 15.9 to
2,748.31 pg/mL, with a mean value of 708.4 – 769.6
pg/mL. No significant differences were noted for
sFas and sFasL among groups (see supplementary
Fig. 1 in online Journal of Periodontology).
Serum Analyses
Five patients were excluded from serum analysis
because of technical problems in acquiring a blood
Figure 1.
DNA fragmentation correlation of disease status with PD. The correlation coefficients comparing the
optical density (OD) to PDs were analyzed by non-parametric two-tailed test to compare the mean
coefficients between healthy, mild CP, and moderate/severe CP groups. A definite positive linear correlation
can be observed between the OD values of DNA fragmentation and PD. This correlation increases in
strength from the healthy/gingivitis group to the moderate/severe CP group. It was found that with a 1-mm
increase in PD, on average, OD increases by 0.27.
*** SAS statistical package, SAS Institute, Cary, NC.
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sample. sFasL concentrations in serum ranged from
15.5 to 113.17 pg/mL, with a mean value of 50.86 –
20.54 pg/mL. sFas concentrations in serum ranged
from 124.1 to 3,479.45 pg/mL, with a mean value of
827.48 – 641.63 pg/mL. No significant difference
among groups for sFasL or sFas was noted (see
supplementary Fig. 1 in online Journal of Periodon-
tology). Caspase-3 was not detected in serum.
GCF Analyses
In GCF, PD and CAL were significantly correlated
with DNA fragmentation (P <0.001; Figs. 1 and 2).
Increases in PD and CAL were analyzed using the
basic unit of measurement, which was millimeters.
Within a patient, a 1-mm increase in PD correlated
with an average increase of 0.2 DNA fragmentation
optical density (OD) units (P <0.001; Figs. 1 and 2A).
Similarly, with each 1-mm increase in CAL, there was
an average increase of 0.12 OD units of DNA frag-
mentation (P <0.001; Fig. 2B). A trend toward lower
DNA fragmentation values was observed among
healthy patients when compared with moderate/
severe CP patients (-0.1505), but the difference was
not significant (Table 2).
The odds of detecting apoptoticmarker expression
using Western blot analysis increased with every
1-mm increase in PD (see supplementary Table 1 in
online Journal of Periodontology). In addition, the
frequency of biomarker expres-
sion increased as disease se-
verity increased for all apoptosis
factors except FasL (Table 3).
FasL expression was signifi-
cantly increased in both the
mild and moderate/severe CP
groups compared with healthy
controls (P = 0.007 and P =
0.045, respectively; Table 3).
The presence of apoptosis
factors Fas, procaspase, and
active procaspase were signif-
icantly correlated with PD
(P <0.05; Table 3). In addition,
there was a trend toward sta-
tistical significance for FasL
and active FasL. For every 1-
mm increase in PD, there was
a 19%, 17%, and 27% greater
odds that Fas, procaspase, and
active caspase were detected
at that site, respectively. Simi-
larly, CAL was a statistically
significant predictor for all apo-
ptosis factors (P <0.05; Table 3).
For every 1-mm increase in
CAL, there was a 12%, 12%,
16%, 9%, and 18% greater odds
that Fas, FasL, active FasL,
procaspase, and active caspase
could be detected at that site,
respectively.
When inflammation was pres-
ent (designated by Classifica-
tion 1, which included sites
positive for both BOP and GI),
there was a statistically signif-
icant OR for detecting active
FasL, procaspase, and active
caspase in GCF (P <0.05; Table
3). When sites were analyzed
Figure 2.
Correlation of DNA fragmentation with PD and CAL. A) A box plot demonstrating the correlation of
DNA fragmentation with PD. Overall, the mean concentration of DNA fragmentation in GCF increased as
the PD increased (P <0.001). Within a patient, a PD increase of 1 mm showed an average increase of
0.2 DNA fragmentation optical density (OD) units (P <0.001).B)A box plot demonstrating the correlation
of DNA fragmentation with CAL. Overall, the mean concentration of DNA fragmentation in GCF increased
as the attachment loss increased (P <0.001) Within a patient, with a 1-mm increase in CAL, there was
an average increase of 0.12 OD units of DNA fragmentation (P <0.001).
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for the presence of BOP, GI, and PD ‡5 mm (Clas-
sification 2), a stronger association was noticed with
respect to biomarker expression of Fas, active FasL,
procaspase, and active caspase (P <0.05; Table 3).
DISCUSSION
There is increasing evidence that apoptosis plays
a role in the pathogenesis of periodontal disease.
However, little is known about the release of apo-
ptotic proteins into GCF, saliva, and serum during
periodontal breakdown in patients. To the best of the
authors’ knowledge, this study is the first to detect
these apoptotic markers in GCF. In addition, this is
the first investigation of these apoptotic molecules in
the saliva and serum of periodontally diseased pa-
tients.
Apoptosis occurs as part of normal cell turnover in
health but increases in response to challenges within
the oral cavity. Periopathogenic bacteria directly
promote apoptosis of epithelial cells and gingival
fibroblasts, exacerbating periodontal breakdown.
In addition, apoptosis of these cells triggers the re-
lease of proinflammatory cytokines, which further
perpetuates the disease progression.30 Traditional
methods of disease recognition, such as changes in
radiographic bone height, may be less timely be-
cause it takes several months for bone loss to be-
come apparent radiographically.
Apoptosis can be induced either intrinsically or
extrinsically. The extrinsic pathway is most rele-
vant for periodontium-associated cellular apoptosis
caused by exposure to periodontal pathogens. This
signaling pathway involves binding of Fas or tumor
necrosis factor-a (TNF-a) and subsequent activation
of caspase.31,32 Bacterially induced cellular apo-
ptosis within the periodontium predominantly affects
connective tissue (CT) cells.8 The majority of cells
undergoing apoptosis are fibroblasts, although
polymorphonuclear leukocytes also undergo a de-
gree of delayed apoptosis.33 In contrast, some leu-
kocytes, macrophages, or other inflammatory cells
become apoptotic as a result of periopathogenic
Table 2.
Correlations Using Generalized Estimating
Equations of DNA Fragmentation With
Disease Status, PD, and CAL







Output from the mixed ANOVA models correlating DNA fragmentation OD
values with disease status, PD, and CAL. Pr = probability.
* P <0.05, statistically significant.
Table 3.
Correlation Between the Presence of the Apoptotic Biomarkers in GCF (predictors) and
PD, CAL, and GI (outcomes) Using Generalized Estimating Equations
OR PD CAL Mild Disease Moderate/Severe Disease Classification 1 Classification 2
Fas
OR 1.19 1.12 0.95 1.14 1.33 2.08
P value 0.001 <0.001 0.98 0.81 0.05 0.01
FasL
OR 1.11 1.12 5.54 3.65 1.25 1.55
P value 0.06 0.006 0.007 0.045 0.15 0.14
Active FasL
OR 1.16 1.16 1.83 2.02 1.54 2.53
P value 0.06 0.004 0.434 0.224 0.002 0.01
Procaspase
OR 1.17 1.09 1.62 1.62 1.35 3.18
P value 0.002 0.03 0.39 0.41 0.02 0.001
Active caspase
OR 1.27 1.18 1.37 1.41 1.68 4.04
P value <0.001 0.001 0.62 0.60 0.001 <0.001
Classification 1 = sites positive for BOP and GI; Classification 2 = sites positive for BOP, GI, and PD ‡5 mm.
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bacterial interactions.8 An exception to this is
Aggregatibacter actinomycetemcomitans (Aa), a viru-
lent bacteria associated with aggressive periodontitis.
Aa produces leukotoxin capable of inducing apo-
ptosis in lymphocytes but sparing CT cells, such as
fibroblasts.34
In a study of Aa-induced periodontitis in rats,
factors known to induce apoptosis, such as TNF-a
and FasL, were upregulated.35 This was associated
with bone loss, indicating that apoptosis may have
clinical relevance in periodontitis. In another study
involving oral inoculation of Aa in rats with diabetes,
inflammation and bone loss were associated with
gingival epithelial and CT cell apoptosis. The authors
postulated high TNF-a production, a potent inducer
of apoptosis mediated by caspase 3, as a potential
mechanism to explain their results.36
The progression of periodontal disease is affected
by apoptosis. Fibroblasts are the primary cell type
affected by apoptosis, and their death leads to loss of
CT strength and subsequent attachment loss.37,38
Epithelial cell apoptosis results in reduced integrity
of the pocket barrier, allowing bacterial infiltration
into the gingival tissues.39 This makes treatment
more difficult, especially when tissue-invasive bac-
teria are involved.
Importantly, to the best of the authors’ knowledge,
this study is the first to demonstrate that apoptotic
proteins and DNA fragments can be found in the
GCF of patients with periodontal disease. Only one
previous study was conducted in this area and re-
ported non-detectable levels of sFas protein in the
GCF of 36 patients with various degrees of peri-
odontal disease.2 The ability to successfully detect
apoptosis factors in the present study may be at-
tributable to the insertion of the GCF paper strips to
the base of the sulcus and the use of Western
blotting instead of ELISA detection methods. Pre-
vious studies have demonstrated that the cells un-
dergoing apoptosis at inflamed sites are located in
the apical third of the sulcus, near the junctional
epithelium.20,40
Because the presence of a group of traditional
disease indicators is more accurate in determining
inflammation and disease activity,26,41 sites were
considered inflamed only when positive for both BOP
and GI. Furthermore, it is well documented that the
risk of periodontal breakdown increases in patients
with residual PD ‡5 mm.26 In this study, sites with
PD ‡5 mm that are positive for GI and BOP simul-
taneously have significantly greater odds of apo-
ptosis factor expression, with the exception of FasL.
The findings for FasL expression may be attributed to
the difference in sample size among groups. How-
ever, additional studies are needed to explain this
difference.
At the site level, the presence of Fas, FasL,
caspase-3, and DNA fragmentation were associated
with clinical signs of periodontitis as well as in-
flammation. After controlling for sex and smoking,
these were not confounding factors in the study,
contrary to previous findings.42 At the patient level,
the lack of significant differences in biomarker ex-
pression could be attributable to high patient vari-
ability, lack of specificity to host response, or
influence of the host microflora, which was not
evaluated.
Only one apoptosis factor, FasL, had statistically
greater odds of being expressed in the mild CP
group when compared with the healthy/gingivitis
group. This could be attributable to dilution of the
effect of diseased sites pooled with healthy sites
because the number of pockets with PD £3 mm
accounted for 75% of the sampled sites. Fur-
thermore, it is possible that other systemic factors,
such as inflammation in other parts of the body,
could act as a confounding factor, also accounting
for a lack of difference. It is noteworthy that the
majority of studies evaluating apoptosis factors in
GCF have limited their site selection to diseased
sites in each patient2 rather than the mesial site of
each tooth present as in the present study.
Apoptotic markers were also detected in shallow
PDs, which might indicate that cells in these sites
were undergoing apoptosis and tissue breakdown, or
even simple homeostatic cell and tissue turnover at
that time point. Also, the expression observed in
these healthy sites and/or gingivitis sites might
suggest that these sites appear to be progressing to
periodontitis sites.
Unfortunately, because of the limited amount of
GCF volume collected per site, normalization by
protein concentration was not feasible. Thus, in the
present study, despite efforts to standardize the po-
tential factors that could affect the GCF samples,
because of the limited sample volume available for
analysis and the inability to find an appropriate
control for normalization, qualitative data were re-
ported instead of using concentrations.
The final pathway in apoptosis is initiated by
caspase-3 and ends with DNA fragmentation, which
is a hallmark of apoptosis. One other group mea-
sured the degree of host b-globin DNA fragmentation
in GCF and reported higher levels of DNA fragments
in patients with periodontitis compared with gingivitis
or healthy patients.43 These data are consistent with
the positive correlation between DNA fragmentation
with CAL and PD reported in the present study.
Serum sampling was performed to validate the re-
lationship between saliva and serum with local disease
in the oral cavity relative to circulating levels of factors
associated with apoptosis. Mean concentrations of
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sFas and sFasL in serum were greater than the mean
concentration in saliva, in accordance with other
studies,44,45 suggesting that the apoptotic proteins
present in serum might have an additional systemic
contribution. The effect of factors expressed from the
small fraction of sites undergoing apoptosis might
be reduced or diluted in the larger volume of saliva,
which might explain the lack of correlation among
study groups.
Caspase-3 has been shown in the literature to be
increased in the serum of patients suffering from
hepatitis C,18,46 cancer,47 rheumatoid arthritis,48 and
heart disease.49 Another study demonstrated that
apoptotic factors in the GCF correlated directly with
PD.50 However, in the present study, caspase-3 was
observed in detectable levels in GCF and not de-
tected in saliva and serum, which indicates that
caspase-3 is activated and secreted locally by the
mesenchymal cells, such as gingival and peri-
odontal ligament fibroblasts and/or macrophages
and neutrophils, into the GCF and not derived from
systemic contribution or saliva contamination. It
also suggests that caspase-3 might have a shorter
half-life that is easily captured in GCF in which the
cells are undergoing apoptosis rather than at distant
sites in saliva or serum. Finally, the different
methods used to detect caspase-3 in GCF com-
pared with saliva and serum may partially explain
the reason for this variability.
To date, no single protein biomarker has proven to
be reliable in the clinical setting. Given the complex
nature of periodontal disease, it is unlikely that a sole
factor exists for disease detection and disease pre-
diction, and the examination of multiple apoptosis
factors or clusters at once might be a more appro-
priate method for disease status determination.51,52
The findings in this study may give insight into the
role of apoptosis in periodontal disease pathogenesis
and highlight the potential role of apoptotic mole-
cules in periodontal disease prediction. This new
knowledge may lead to strategies to prevent or
modulate periodontal disease, including the de-
velopment of agents to limit or modify apoptosis.
CONCLUSIONS
This pilot study demonstrates that factors associated
with apoptosis are detected in GCF. Nevertheless, one
should exercise caution in interpreting these prom-
ising findings. Additional studies involving longitu-
dinal assessments with larger populations and the use
of more sensitive methods for detection are needed to
confirm the findings.
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